Skip to main
LLY
LLY logo

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly reported a strong performance in the second quarter of 2025, exceeding expectations on both revenue and earnings, while also raising its full-year guidance. The company experienced a significant 60% quarter-over-quarter growth in international sales of Mounjaro, enhanced by successful launches in new markets such as Brazil, Mexico, and India. This robust sales momentum, particularly in key product lines, underscores Eli Lilly's solid market position and potential for continued financial growth.

Bears say

Eli Lilly has experienced a notable decline in the prescription volume of Zepbound in July, which is anticipated to adversely affect volumetric growth in the third quarter. The company faces several downside risks, including potential pricing pressures and an unfavorable trajectory for tirzepatide (Mounjaro), especially concerning its efficacy in demonstrating cardiac outcomes in both diabetic and non-diabetic obese patients. Additionally, heightened competition from drugs like orforglipron and a downward revision of its peak sales forecasts further contribute to a challenging outlook for the firm.

Eli Lilly (LLY) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 16 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $966.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $966.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.